Expedition Therapeutics, Inc.

Founded in 2024, based in California, US, Expedition Therapeutics Inc. operates a biotechnology company focused on developing targeted therapies for cancer. Leveraging advanced molecular profiling and translational research, the firm aims to deliver precision oncology solutions that improve patient outcomes. Its mission centers on innovation, collaboration, and accelerating the path from discovery to clinical impact.

The company was founded by Yi Larson (CEO). In August 2026, Expedition Therapeutics Inc. raised USD 115 million in series B funding led by General Atlantic, with participation from RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Expedition Therapeutics focuses on developing innovative treatments specifically targeting inflammatory and respiratory diseases, primarily chronic obstructive pulmonary disease (COPD).

Their lead product, EXPD-101, is an oral DPP1 inhibitor designed to address neutrophilic inflammation—an underlying mechanism that exacerbates tissue damage and lung function decline in COPD patients. The therapy aims to provide a disease-controlling option for nearly 70% of COPD patients who currently lack effective treatment alternatives. Additionally, the company is exploring the potential of EXPD-101 in related conditions such as bronchiectasis and neutrophilic asthma, thereby broadening its applicability. Expedition Therapeutics targets both the North American and European markets, seeking to deliver its advanced therapeutic solutions to a wide range of healthcare providers and patients globally.

Expedition Therapeutics recently completed a substantial USD 165 mn Series A financing round, indicating strong investor confidence and support for the company’s mission. Revenue generation primarily revolves around partnerships and collaborations with pharmaceutical companies, healthcare providers, and research institutions that seek to leverage their innovative therapies. The transactions are expected to be structured around licensing agreements, clinical trial collaborations, and potentially direct sales once products receive regulatory approval and market entry. Flagship product EXPD-101 is anticipated to be central to these revenue streams, as it transitions into further clinical trials and prepares for commercialization.

The company is planning to use the August 2026 funding to advance the development of its COPD treatment program, including its Phase 2 clinical trial for EXPD-101.